Supportive Care in Cancer

, Volume 15, Issue 12, pp 1407–1412 | Cite as

Symptom and medication profiles among cancer patients attending a palliative care clinic

  • Rachel P. Riechelmann
  • Monika K. Krzyzanowska
  • Aoife O’Carroll
  • Camilla ZimmermannEmail author
Original Article



Patients with advanced cancer frequently experience distressful symptoms and receive numerous medications. We describe the symptomatology and medication profile of ambulatory cancer patients receiving exclusively supportive care at the Princess Margaret Hospital.

Materials and methods

This was a retrospective, cross-sectional study. We reviewed the charts of consecutive adult cancer patients attending palliative care clinics and who were no longer receiving cancer-directed therapy. From the medical records, we collected information about self-reported symptoms [screened for with the numerical Edmonton symptom assessment system (ESAS) scale; range, 0–10, with 10=worst symptom] and medication profiles. Summary statistics were used to describe the results.


Two hundred fifty five patients met the inclusion criteria. The most frequent self-reported symptoms of any severity were fatigue (77%), pain (75%), and lack of appetite (66%). These were also the most severe symptoms: fatigue (median ESAS score=7), pain (median ESAS=5), and lack of appetite (median ESAS=5). The median number of medications per patient after consultation in the palliative care service was 6, and the most common classes of drugs prescribed were opioids (67%), laxatives/stool softeners (54%), corticosteroids (41%), and acetaminophen (41%). Palliative care physicians made at least one medication change in 75% of the patients, with the most frequent change being the addition of new medication(s); dexamethasone was the most commonly added individual drug (18% of the patients).


Among patients with advanced cancer not receiving antineoplastic therapy, the most frequent and severe symptoms were fatigue, pain, and lack of appetite. The medication profile represented drugs that could both alleviate and contribute to these symptoms. Audit of patient symptoms and medication prescription in palliative care may inform clinical practice and help the development of research specific to patient symptoms.


Palliative care clinic Antineoplastic therapy Ambulatory cancer Symptom assessment 


  1. 1.
    Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRefGoogle Scholar
  2. 2.
    Mancini I, Lossignol D, Obiols M et al (2002) Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer 10:3–7PubMedCrossRefGoogle Scholar
  3. 3.
    Elsayem A, Swint K, Fisch MJ et al (2004) Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 22:2008–2014PubMedCrossRefGoogle Scholar
  4. 4.
    Riechelmann RP, Tannock IF, Wang L, Krzyzanowska MK (2006) Drug interactions in ambulatory cancer patients receiving cancer-therapy. Proc Am Soc Clin Oncol volume 24: abstract # 6129Google Scholar
  5. 5.
    Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290PubMedCrossRefGoogle Scholar
  6. 6.
    Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11:27–32PubMedGoogle Scholar
  7. 7.
    Jenkins CA, Schulz M, Hanson J et al (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19:174–184PubMedCrossRefGoogle Scholar
  8. 8.
    Stromgren AS, Sjogren P, Goldschmidt D et al (2006) Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 31:199–206PubMedCrossRefGoogle Scholar
  9. 9.
    Stromgren AS, Sjogren P, Goldschmidt D et al (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755PubMedCrossRefGoogle Scholar
  10. 10.
    Stromgren AS, Goldschmidt D, Groenvold M et al (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520PubMedCrossRefGoogle Scholar
  11. 11.
    Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRefGoogle Scholar
  12. 12.
    Twycross RG, Bergl S, John S et al (1994) Monitoring drug use in palliative care. Palliat Med 8:137–143PubMedGoogle Scholar
  13. 13.
    Koh NY, Koo WH (2002) Polypharmacy in palliative care: can it be reduced? Singap Med J 43:279–283Google Scholar
  14. 14.
    Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17:37–40PubMedGoogle Scholar
  15. 15.
    Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8:312–316PubMedCrossRefGoogle Scholar
  16. 16.
    Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987PubMedCrossRefGoogle Scholar
  17. 17.
    Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMedGoogle Scholar
  18. 18.
    Bernhard J, Cella DF, Coates AS et al (1998) Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:517–532PubMedCrossRefGoogle Scholar
  19. 19.
    Drummond SH, Peterson GM, Galloway JG et al (1996) National survey of drug use in palliative care. Palliat Med 10:119–124PubMedGoogle Scholar
  20. 20.
    Prue G, Rankin J, Allen J et al (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRefGoogle Scholar
  21. 21.
    Lundstrom SH, Furst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437PubMedCrossRefGoogle Scholar
  22. 22.
    Ashbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Rachel P. Riechelmann
    • 1
  • Monika K. Krzyzanowska
    • 1
  • Aoife O’Carroll
    • 1
  • Camilla Zimmermann
    • 2
    Email author
  1. 1.Department of Medical Oncology and Hematology, Princess Margaret HospitalUniversity of TorontoTorontoCanada
  2. 2.Department of Psychosocial Oncology and Palliative Care, Princess Margaret HospitalUniversity of TorontoTorontoCanada

Personalised recommendations